Thymidylate synthase and tumor

doi:10.3760/cma.j.cn371439-20200318-00088

Abstract

Abstract:

Thymidylate synthase (TS) is a key enzyme in DNA synthesis and is often used as a target for chemotherapy drugs. In a variety of tumors such as non-small cell lung cancer, colorectal cancer, breast cancer, etc, the expression of TS is closely related to the clinical prognosis and chemotherapy drug resistance of patients. Reducing the expression of TS in tumor tissues through various molecular mechanisms has become an important means to improve the efficacy of chemotherapy drugs and improve the clinical prognosis.

Key words: Neoplasms, Drug resistance, Thymidylate synthase

Huang Zhiguo, Hu Kongwang. Thymidylate synthase and tumor[J]. Journal of International Oncology, 2020, 47(10): 615-618.

References 33

[1]	Li XY, Liang JW, Mohamed OK, et al. Design, synjournal and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs[J]. Eur J Med Chem, 2018,154:267-279. DOI: 10.1016/j.ejmech.2018.05.020. pmid: 29807332
[2]	Lu GQ, Li XY, Mohamed OK, et al. Design, synjournal and biological evaluation of novel uracil derivatives bearing 1, 2, 3, -triazole moiety as thymidylate synthase (TS) inhibitors and as potential antitumor drugs[J]. Eur J Med Chem, 2019,171:282-296. DOI: 10.1016/j.ejmech.2019.03.047.
[3]	Kang M, Zheng W, Chen Q, et al. Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma[J]. Cancer Lett, 2018,419:40-52. DOI: 10.1016/j.canlet.2018.01.026. pmid: 29331423
[4]	Wang L. Mitochondrial purine and pyrimidine metabolism and beyond[J]. Nucleosides Nucleotides Nucleic Acids, 2016,35(10-12):578-594. DOI: 10.1080/15257770.2015.1125001.
[5]	Kulda V, Hrda K, Houdek Z, et al. Predictive significance of thymidylate synthase expression in non-small cell lung cancer[J]. Anticancer Res, 2017,37(12):6953-6958. DOI: 10.21873/anticanres.12161. doi: 10.21873/anticanres.12161 pmid: 29187479
[6]	Yang M, Fan WF, Pu XL, et al. The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy[J]. J Chemother, 2017,29(2):106-112. DOI: 10.1080/1120009X.2016.1254940.
[7]	Miura K, Oba T, Hamanaka K, et al. FGF2-FGFR1 pathway activation together with thymidylate synthase upregulation is induced in pemetrexed-resistant lung cancer cells[J]. Oncotarget, 2019,10(11):1171-1192. DOI: 10.18632/oncotarget.26622. doi: 10.18632/oncotarget.26622 pmid: 30838090
[8]	Chamizo C, Zazo S, Dómine M, et al. Thymidylate synthase expre-ssion as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer[J]. BMC Pulm Med, 2015,15:132. DOI: 10.1186/s12890-015-0132-x.
[9]	Kuo WT, Tu DG, Chiu LY, et al. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase[J]. Oncol Rep, 2017,38(5):2787-2795. DOI: 10.3892/or.2017.5951.
[10]	Chen CY, Chen YY, Chen JJW, et al. Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression[J]. Oncotarget, 2017,8(37):61901-61916. DOI: 10.18632/oncotarget.18717. pmid: 28977913
[11]	Liao KS, Wei CL, Chen JC, et al. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells[J]. Regul Toxicol Pharmacol, 2016,81:353-361. DOI: 10.1016/j.yrtph.2016.09.031. doi: 10.1016/j.yrtph.2016.09.031 pmid: 27693704
[12]	Tung CL, Chen JC, Wu CH, et al. Salinomycin acts through redu-cing AKT-dependent thymidylate synthase expression to enhance erlotinib-induced cytotoxicity in human lung cancer cells[J]. Exp Cell Res, 2017,357(1):59-66. DOI: 10.1016/j.yexcr.2017.04.026. doi: 10.1016/j.yexcr.2017.04.026 pmid: 28454878
[13]	Ko JC, Chen JC, Yen TC, et al. Nitroglycerin enhances cisplatin-induced cytotoxicity via AKT inactivation and thymidylate synthase downregulation in human lung cancer cells[J]. Pharmacology, 2020,105(3-4):209-224. DOI: 10.1159/000503688. pmid: 31630149
[14]	Bai W, Wu Y, Zhang P, et al. Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer[J]. Int J Clin Exp Pathol, 2015,8(10):12333-12345.
[15]	Jiang H, Li B, Wang F, et al. Expression of ERCC1 and TYMS in colorectal cancer patients and the predictive value of chemotherapy efficacy[J]. Oncol Lett, 2019,18(2):1157-1162. DOI: 10.3892/ol.2019.10395.
[16]	Torén W, Ansari D, Andersson B, et al. Thymidylate synthase: a predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment[J]. Future Oncol, 2018,14(4):343-351. DOI: 10.2217/fon-2017-0431. pmid: 29318904
[17]	Chen S, Yue T, Huang Z, et al. Inhibition of hydrogen sulfide synjournal reverses acquired resistance to 5-FU through miR-215-5p-EREG/TYMS axis in colon cancer cells[J]. Cancer Lett, 2019,466:49-60. DOI: 10.1016/j.canlet.2019.09.006. doi: 10.1016/j.canlet.2019.09.006 pmid: 31542354
[18]	Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells[J]. Carcinogenesis, 2019,40(3):422-431. DOI: 10.1093/carcin/bgy186. pmid: 30590435
[19]	Varghese V, Magnani L, Harada-Shoji N, et al. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expre-ssion[J]. Sci Rep, 2019,9(1):1505. DOI: 10.1038/s41598-018-38017-0. pmid: 30728402
[20]	Jiang B, Liu F, Liu Z, et al. B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway[J]. Tumour Biol, 2016,37(7):9465-9472. DOI: 10.1007/s13277-015-4740-0. doi: 10.1007/s13277-015-4740-0 pmid: 26787540
[21]	Ahn JY, Lee JS, Min HY, et al. Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expre-ssion in colon cancer[J]. Oncotarget, 2015,6(32):32622-32633. DOI: 10.18632/oncotarget.5327.
[22]	Zhou YH, Liu Y, Zhang W, et al. Associations between clinical-pathological parameters and biomarkers, HER-2, TYMS, RRMI, and 21-gene recurrence score in breast cancer[J]. Pathol Res Pract, 2019,215(11):152644. DOI: 10.1016/j.prp.2019.152644.
[23]	Shan F, Liu YL, Wang Q, et al. Thymidylate synthase predicts poor response to pemetrexed chemotherapy in patients with advanced breast cancer[J]. Oncol Lett, 2018,16(3):3274-3280. DOI: 10.3892/ol.2018.8973. doi: 10.3892/ol.2018.8973 pmid: 30127925
[24]	Matsumoto A, Hayashida T, Takahashi M, et al. Antitumor effect of lapatinib and cytotoxic agents by suppression of E2F1 in HER2-positive breast cancer[J]. Mol Med Rep, 2018,18(1):958-964. DOI: 10.3892/mmr.2018.9068.
[25]	Siddiqui A, Gollavilli PN, Schwab A, et al. Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers[J]. Cell Death Differ, 2019,26(11):2223-2236. DOI: 10.1038/s41418-019-0289-6. doi: 10.1038/s41418-019-0289-6 pmid: 30737477
[26]	Li X, Kong X, Kong X, et al. 53BP1 sensitizes breast cancer cells to 5-fluorouracil[J]. PLoS One, 2013,8(9):e74928. DOI: 10.1371/journal.pone.0074928. doi: 10.1371/journal.pone.0074928 pmid: 24040364
[27]	Pereira MA, Ramos MFKP, Dias AR, et al. Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy[J]. Chin J Cancer Res, 2018,30(5):526-536. DOI: 10.21147/j.issn.1000-9604.2018.05.06. pmid: 30510364
[28]	Wang D, Yu X, Wang X. High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis[J]. Int J Biol Markers, 2016,31(2):e101-e109. DOI: 10.5301/jbm.5000202. doi: 10.5301/jbm.5000202 pmid: 27012156
[29]	Donner DB, Nakakura EK, Venook AP, et al. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma[J]. PLoS One, 2019,14(7):e0219469. DOI: 10.1371/journal.pone.0219469. pmid: 31291332
[30]	Shimizu A, Kaira K, Yasuda M, et al. Prognostic significance of thymidylate synthase (TS) expression in cutaneous malignant melanoma[J]. Neoplasma, 2016,63(2):282-287. DOI: 10.4149/215-150714N389.
[31]	Burdelski C, Strauss C, Tsourlakis MC, et al. Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer[J]. Oncotarget, 2015,6(10):8377-8387. DOI: 10.18632/oncotarget.3107. doi: 10.18632/oncotarget.3107 pmid: 25762627
[32]	Fu Z, Jiao Y, Li Y, et al. TYMS presents a novel biomarker for diagnosis and prognosis in patients with pancreatic cancer[J]. Medicine (Baltimore), 2019,98(51):e18487. DOI: 10.1097/MD.0000000000018487.
[33]	Intuyod K, Saavedra-Garcia P, Zona S, et al. FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance[J]. Cell Death Dis, 2018,9(12):1185. DOI: 10.1038/s41419-018-1235-0. pmid: 30538221